GlaxoSmithKline Czech Republic

GlaxoSmithKline CR's employees fell 14.5% to 141 in 2017

By Helgi Analytics - November 05, 2019

GlaxoSmithKline Czech Republic employed 141 persons in 2017, down 14.5% when compared to the previous year. Historically, the firm's...

GlaxoSmithKline CR's net profit rose 72.0% to CZK 65.4 mil in 2017

By Helgi Analytics - November 05, 2019

GlaxoSmithKline Czech Republic made a net profit of CZK 65.4 mil in 2017, up 72.0% when compared to the last year. Total sales reach...

GlaxoSmithKline CR's Capital Expenditures fell 71.6% to CZK 2.22 mil in 2017

By Helgi Analytics - November 05, 2019

GlaxoSmithKline Czech Republic invested total of CZK 2.22 mil in 2017, down 71.6% when compared to the previous year. His...

Profit Statement 2015 2016 2017
Sales CZK mil 4,378 3,393 2,897
Gross Profit CZK mil 497 384 335
EBITDA CZK mil 139 62.4 97.4
EBIT CZK mil 127 54.1 89.9
Financing Cost CZK mil 1.37 0.602 0.858
Pre-Tax Profit CZK mil 156 53.5 89.0
Net Profit CZK mil 125 38.0 65.4
Dividends CZK mil 125 38.0 ...
Balance Sheet 2015 2016 2017
Total Assets CZK mil 2,107 1,524 1,520
Non-Current Assets CZK mil 18.8 16.2 10.1
Current Assets CZK mil 2,066 1,493 1,496
Working Capital CZK mil 983 1,049 1,154
Shareholders' Equity CZK mil 1,338 1,524 1,520
Liabilities CZK mil 768 0 0
Total Debt CZK mil 0 0 0
Net Debt CZK mil -515 -350 -209
Ratios 2015 2016 2017
ROE % 9.44 2.66 4.30
ROCE % 11.2 3.68 5.87
Gross Margin % 11.4 11.3 11.6
EBITDA Margin % 3.17 1.84 3.36
EBIT Margin % 2.91 1.59 3.10
Net Margin % 2.85 1.12 2.26
Net Debt/EBITDA -3.71 -5.61 -2.15
Net Debt/Equity % -38.5 -23.0 -13.8
Cost of Financing % ... ... ...
Cash Flow 2015 2016 2017
Total Cash From Operations CZK mil ... -142 -78.2
Total Cash From Investing CZK mil ... -7.05 -1.83
Total Cash From Financing CZK mil ... -125 -38.0
Net Change In Cash CZK mil ... -274 -118
Cash Conversion Cycle days 85.4 119 155
Cash Earnings CZK mil 136 46.4 72.9
Free Cash Flow CZK mil ... -150 -80.1

Get all company financials in excel:

Download Sample   $19.99

summary Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
income statement                              
Sales CZK mil                 5,828 5,735 5,653 4,855 4,378    
Gross Profit CZK mil                 622 710 653 596 497    
EBIT CZK mil                 291 216 169 119 127    
Net Profit CZK mil                 240 164 127 87.7 125    
ROE %                 19.3 12.0 9.41 6.64 9.44    
EBIT Margin %                 5.00 3.76 2.98 2.46 2.91    
Net Margin %                 4.12 2.86 2.25 1.81 2.85    
Employees                 264 262 239 246 183    
balance sheet                              
Total Assets CZK mil                 3,166 2,418 2,374 2,019 2,107    
Non-Current Assets CZK mil                 41.0 57.7 47.5 33.7 18.8    
Current Assets CZK mil                 3,084 2,321 2,295 1,959 2,066    
Shareholders' Equity CZK mil                 1,363 1,369 1,340 1,301 1,338    
Liabilities CZK mil                 1,802 1,050 1,034 718 768    
Non-Current Liabilities CZK mil                 55.0 59.5 91.3 61.5 55.7    
Current Liabilities CZK mil                 1,747 990 943 656 713    
Net Debt/EBITDA                 0.438 1.02 1.69 -0.001 -3.71    
Net Debt/Equity %                 9.97 17.5 23.8 -0.015 -38.5    
Cost of Financing % ...               1.64 1.09 1.94 1.42 ... ... ...
cash flow                              
Total Cash From Operations CZK mil           ... ... ... ... ... ... ... ...    
Total Cash From Investing CZK mil           ... ... ... ... ... ... ... ...    
Total Cash From Financing CZK mil           ... ... ... ... ... ... ... ...    
Net Change In Cash CZK mil           ... ... ... ... ... ... ... ...    
income statement Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
income statement                              
Sales CZK mil                 5,828 5,735 5,653 4,855 4,378    
Cost of Goods & Services CZK mil                 5,207 5,026 5,000 4,259 3,880    
Gross Profit CZK mil                 622 710 653 596 497    
Staff Cost CZK mil                 284 315 335 349 298    
Other Cost CZK mil                 27.6 161 129 107 61.1    
EBITDA CZK mil                 310 234 189 139 139    
Depreciation CZK mil                 19.3 18.3 19.9 20.2 11.6    
EBIT CZK mil                 291 216 169 119 127    
Financing Cost CZK mil                 4.67 3.27 5.44 2.27 1.37    
Extraordinary Cost CZK mil                 0 0 0 0 -30.0    
Pre-Tax Profit CZK mil                 286 212 163 117 156    
Tax CZK mil                 46.4 48.6 35.8 29.3 25.6    
Minorities CZK mil                 0 0 0 0 0    
Net Profit CZK mil                 240 164 127 87.7 125    
Dividends CZK mil ... ... ... ... ... ... ... ... ... ... ... ... 125   ...
growth rates                              
Total Revenue Growth % ...               -5.48 -1.59 -1.43 -14.1 -9.83    
Operating Cost Growth % ...               -34.4 52.8 -2.39 -1.60 -21.5    
EBITDA Growth % ...               27.4 -24.7 -19.4 -26.0 -0.486    
EBIT Growth % ...               31.9 -25.9 -21.8 -29.3 6.70    
Pre-Tax Profit Growth % ...               32.4 -25.9 -23.1 -28.4 33.3    
Net Profit Growth % ...               45.3 -31.8 -22.2 -31.2 42.1    
ratios                              
ROE %                 19.3 12.0 9.41 6.64 9.44    
ROCE % ...               14.3 9.26 6.91 5.65 11.2    
Gross Margin %                 10.7 12.4 11.5 12.3 11.4    
EBITDA Margin %                 5.33 4.08 3.34 2.87 3.17    
EBIT Margin %                 5.00 3.76 2.98 2.46 2.91    
Net Margin %                 4.12 2.86 2.25 1.81 2.85    
Payout Ratio % ... ... ... ... ... ... ... ... ... ... ... ... 100   ...
Cost of Financing % ...               1.64 1.09 1.94 1.42 ... ... ...
Net Debt/EBITDA                 0.438 1.02 1.69 -0.001 -3.71    
balance sheet Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
balance sheet                              
Non-Current Assets CZK mil                 41.0 57.7 47.5 33.7 18.8    
Property, Plant & Equipment CZK mil                 37.0 50.5 38.6 20.3 11.6    
Intangible Assets CZK mil                 3.56 6.73 8.41 12.9 6.78    
Current Assets CZK mil                 3,084 2,321 2,295 1,959 2,066    
Inventories CZK mil                 1,677 1,163 1,250 813 667    
Receivables CZK mil                 1,114 1,025 918 659 663    
Cash & Cash Equivalents CZK mil                 226 0.438 0.680 0.193 515    
Total Assets CZK mil                 3,166 2,418 2,374 2,019 2,107    
Shareholders' Equity CZK mil                 1,363 1,369 1,340 1,301 1,338    
Of Which Minority Interest CZK mil                 0 0 0 0 0    
Liabilities CZK mil                 1,802 1,050 1,034 718 768    
Non-Current Liabilities CZK mil                 55.0 59.5 91.3 61.5 55.7    
Long-Term Debt CZK mil                 0 0 0 0 0    
Deferred Tax Liabilities CZK mil ...   ... ... ... ... ... ... ... ... ... ... ... ... ...
Current Liabilities CZK mil                 1,747 990 943 656 713    
Short-Term Debt CZK mil                 362 240 320 0 0    
Trade Payables CZK mil                 1,094 445 332 289 347    
Provisions CZK mil                 55.0 57.3 85.1 56.3 51.5    
Equity And Liabilities CZK mil                 3,166 2,418 2,374 2,019 2,107    
growth rates                              
Total Asset Growth % ...               15.9 -23.6 -1.81 -15.0 4.34    
Shareholders' Equity Growth % ...               21.4 0.377 -2.06 -2.90 2.83    
Net Debt Growth % ...               -18.8 76.2 33.3 -100 266,920    
Total Debt Growth % ...               74.0 -33.7 33.3 -100 ... ... ...
ratios                              
Total Debt CZK mil                 362 240 320 0 0    
Net Debt CZK mil                 136 240 319 -0.193 -515    
Working Capital CZK mil                 1,697 1,744 1,837 1,184 983    
Capital Employed CZK mil                 1,739 1,801 1,884 1,218 1,002    
Net Debt/Equity %                 9.97 17.5 23.8 -0.015 -38.5    
Cost of Financing % ...               1.64 1.09 1.94 1.42 ... ... ...
cash flow Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
cash flow                              
Net Profit CZK mil                 240 164 127 87.7 125    
Depreciation CZK mil                 19.3 18.3 19.9 20.2 11.6    
Non-Cash Items CZK mil ...         ... ... ... ... ... ... ... ...    
Change in Working Capital CZK mil ...         ... ... ... ... ... ... ... ...    
Total Cash From Operations CZK mil           ... ... ... ... ... ... ... ...    
Capital Expenditures CZK mil           ... ... ... ... ... ... ... ...    
Other Investments CZK mil           ... ... ... ... ... ... ... ...    
Total Cash From Investing CZK mil           ... ... ... ... ... ... ... ...    
Dividends Paid CZK mil ... ... ... ... ... ... ... ... ... ... ... ... ...    
Issuance Of Shares CZK mil ... ... ... ... ... ... ... ... ... ... ... ... ...    
Issuance Of Debt CZK mil ...         ... ... ... ... ... ... ... ...    
Total Cash From Financing CZK mil           ... ... ... ... ... ... ... ...    
Net Change In Cash CZK mil           ... ... ... ... ... ... ... ...    
ratios                              
Days Sales Outstanding days                 69.8 65.3 59.3 49.6 55.2    
Days Sales Of Inventory days                 118 84.4 91.3 69.7 62.7    
Days Payable Outstanding days                 76.7 32.3 24.2 24.7 32.6    
Cash Conversion Cycle days                 111 117 126 94.5 85.4    
Cash Earnings CZK mil                 259 182 147 108 136    
Free Cash Flow CZK mil           ... ... ... ... ... ... ... ...    
other data Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
other data                              
ROA %                 8.14 5.87 5.32 3.99 6.04    
Gross Margin %                 10.7 12.4 11.5 12.3 11.4    
Employees                 264 262 239 246 183    
Cost Per Employee USD per month                 5,062 5,117 5,978 5,537 5,678    
Cost Per Employee (Local Currency) CZK per month                 89,532 100,080 116,960 118,335 135,534    
Staff Cost (As % Of Total Cost) %                 5.12 5.70 6.12 7.38 7.00    
Effective Tax Rate %                 16.2 22.9 21.9 25.0 16.4    
Capital Expenditures (As % of Sales) %           ... ... ... ... ... ... ... ...    
Revenues From Abroad CZK mil                 2,325 2,423 2,348 1,780 1,501    
Revenues From Abroad (As % Of Total) %                 39.9 42.2 41.5 36.7 34.3    
Domestic Sales of Services CZK mil ... ...             0.588 0 0 0 3.09    
Export of Services CZK mil                 1,960 2,042 2,026 1,529 1,281    
Domestic Sales of Goods CZK mil                 3,503 3,313 3,305 3,075 2,874    
Export of Goods CZK mil                 365 380 322 252 220    

Get all company financials in excel:

Download Sample   $19.99

GlaxoSmithKline CR's Net Margin rose 101% to 2.26% in 2017

By Helgi Analytics - November 05, 2019

GlaxoSmithKline Czech Republic made a net profit of CZK CZK 65.4 mil under revenues of CZK 2,897 mil in 2017, up 72% and -14.6%, respectively, when compared to the last year. This translates into a net margin of 2.26%. Historically, the firm’s net margin reached ...

GlaxoSmithKline CR's Net Debt/EBITDA rose 61.7% to -2.15 in 2017

By Helgi Analytics - November 05, 2019

GlaxoSmithKline Czech Republic's net debt reached CZK -209 mil and accounted for -13.8% of equity at the end of 2017. The ratio is up 40.1% when compared to the previous year. Historically, the firm’s net debt to equity reached an all time high of 40.0% in 2008 and ...

GlaxoSmithKline CR's ROCE rose 59.4% to 5.87% in 2017

By Helgi Analytics - November 05, 2019

GlaxoSmithKline Czech Republic made a net profit of CZK 65.4 mil in 2017, up 72.0% when compared to the previous year. Historically, company's net profit reached an all time high of CZK 240 mil in 2011 and an all time low of CZK -7.67 mil in 2006. This implies ret...

GlaxoSmithKline CR's Cash & Cash Equivalents fell 40.3% to CZK 209 mil in 2017

By Helgi Analytics - November 05, 2019

GlaxoSmithKline Czech Republic's total assets reached CZK 1,520 mil at the end of 2017, up 8.14% when compared to the previous year. Current assets amounted to CZK 1,496 mil, or 98.4% of total assets while cash reached CZK 209 mil at the end of 2017. On the other hand, tot...

GlaxoSmithKline CR's Total Cash From Operations rose 45.1% to CZK -78.2 mil in 2017

By Helgi Analytics - November 05, 2019

GlaxoSmithKline Czech Republic's operating cash flow reached CZK -78.2 mil in 2017, up 45.1% when compared to the previous year. Historically, the firm’s operating cash flow reached an all time high of CZK 192 mil in 2006 and an all time low of CZK -556 mil in 200...

More News

GlaxoSmithKline, s.r.o. is a Czech Republic-based subsidiary of the British multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in Brentford, London. As of March 2014, it was the world's sixth-largest pharmaceutical Company by revenues. The Company was established in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham plc. GSK manufactures drugs and vaccines for major disease areas such as asthma, cancer, infections, diabetes, digestive and mental health conditions, the biggest selling of which were Advair, Avodart, Flovent, Augmentin, Lovaza, and Lamictal.

GlaxoSmithKline Czech Republic Logo